NASDAQ$BTMD
biote Corp · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Biote's financial performance remained relatively stable year-over-year, with revenue slightly decreasing but procedure revenue growing, offset by a decline in dietary supplement revenue, and the company experienced a net loss due to increased investments and changes in the fair value of liabilities.
Biote reported revenue of $49.2 million, a slight decrease from the previous year. Procedure revenue increased, but dietary supplement revenue declined. The company experienced a net loss of $(10.5) million, influenced by increased investments in sales and marketing and changes in the fair value of earnout liabilities.
- Revenue was $49.2 million.
- Procedure revenue grew 7.8% year-over-year.
- Net loss was $(10.5) million, with a loss per share of $(0.19).
- Gross profit margin was 68.9%, including a $1.2 million inventory step-up from the Asteria Health acquisition.
Headline financials
Revenue & EPS history
biote · Revenue · Quarterly
$49.2M
Forward guidance
Biote reiterates its 2024 financial guidance for revenue between $200 million and $204 million and Adjusted EBITDA between $60 million and $63 million, anticipating accelerated growth in the second half of the year and moderating operating expenses.
Tailwinds
- Expect improved procedure revenue growth in the second half of 2024.
- Growth will be driven by strengthened performance from top-tier clinics.
- Growth will be driven by continued expansion of practitioner network.
- Growth will be driven by quick-start program that accelerates the revenue ramp from new clinics.
- Overall operating expenses will moderate in the second half of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2024
-2.4%
Avg return
Earnings day
-4.0%
Avg return
5 days after
-3.0%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+16.9%
Q3 2024
Best reaction
-25.1%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.9% | -9.6% | +4.6% | |
| Q4 2025 | -10.5% | -20.9% | -7.6% | |
| Q3 2025 | -2.4% | -11.1% | -13.0% | |
| Q1 2025 | +11.3% | +17.1% | +14.7% | |
| Q4 2024 | -25.1% | -0.7% | -11.0% | |
| Q3 2024 | +16.9% | -6.3% | +13.7% | |
| Q2 2024 | -21.2% | -17.8% | -10.6% | |
| Q1 2024 | +0.2% | +1.0% | +11.1% | |
| Q4 2023 | +11.9% | +27.0% | +10.1% | |
| Q3 2023 | -20.2% | -18.4% | -0.9% | |
| Q2 2023 | -14.4% | -22.0% | -23.7% | |
| Q1 2023 | -17.2% | -14.3% | -20.6% | |
| Q4 2022 | +16.6% | +34.9% | +33.3% | |
| Q3 2022 | +2.3% | +2.5% | +7.2% | |
| Q2 2022 | +1.1% | -4.6% | -7.4% | |
| Q1 2022 | +0.6% | -36.9% | -64.3% | |
| Q4 2021 | +0.0% | +0.0% | +0.6% | |
| Q3 2021 | -0.1% | +0.1% | +1.0% | |
| Q2 2021 | +0.0% | -0.5% | -0.2% | |
| Q1 2021 | +0.6% | +0.6% | +3.0% | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro